Skip to main content
SpringerLink
Log in
Book cover

Multidisciplinary Approach to Osteoporosis pp 237–255Cite as

Rheumatic Diseases and Osteoporosis

  • Chapter
  • First Online:

  • 674 Accesses

Abstract

Inflammatory joint diseases, such as seronegative spondyloarthropathies, rheumatoid arthritis and systemic lupus erythematosus, are characterized by bone complications including osteoporosis and fragility fractures.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases. Reumatismo. 2014;66:125–35.

    Article  PubMed  CAS  Google Scholar 

  2. Schett G, Saag KG, Bijlsma JWJ. From bone to biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415–9.

    Article  PubMed  CAS  Google Scholar 

  3. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk fractures. J Bone Miner Res. 2000;15:993–1000.

    Article  PubMed  Google Scholar 

  4. Briot K, Roux C. Inflammation, bone loss and fracture risk in spondyloarthritis. RMD Open. 2015;1(1):e000052. https://doi.org/10.1136/rmdopen-2015-000052.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–63.

    Article  PubMed  CAS  Google Scholar 

  6. Haroon NN, Sriganthan J, Al Ghanim N. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:155–61.

    Article  PubMed  CAS  Google Scholar 

  7. Amarasekara DS, Yu J, Rho J. Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. J Immunol Res. 2015;2015:832127. https://doi.org/10.1155/2015/832127.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ghozlani I, Ghazi M, Nouijai A, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2012;44:772–6.

    Article  Google Scholar 

  9. van der Weijden MA, van Denderen JC, Lems WF, et al. Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol. 2011;30:497–503.

    Article  PubMed  Google Scholar 

  10. van der Weijden MA, Claushuis TA, Nazari T, et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31:1529–35.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Klingberg E, Geijer M, Göthlin J, et al. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton. J Rheumatol. 2012;39:1987–95.

    Article  PubMed  Google Scholar 

  12. Karberg K, Zochling J, Sieper J, et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol. 2005;32:1290–8.

    PubMed  Google Scholar 

  13. Leone A, Marino M, Dell’Atti C, et al. Spinal fractures in patients with ankylosing spondylitis. Rheumatol Int. 2016;5(1):51–5. [Epub ahead of print].

    Google Scholar 

  14. Weiss RJ, Wick MC, Ackermann PW, et al. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases – a case-control study with 53,108 patients with fracture. J Rheumatol. 2010;37:2247–50.

    Article  PubMed  Google Scholar 

  15. van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, et al. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int. 2012;23:1683–90.

    Article  PubMed  Google Scholar 

  16. Muñoz-Ortego J, Vestergaard P, Rubio JB, et al. Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res. 2014;29:1770–6.

    Article  PubMed  Google Scholar 

  17. Zhao S, Duffield SJ, Moots RJ, et al. Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. Rheumatology. 2014;53:1595–603.

    Article  PubMed  CAS  Google Scholar 

  18. Goldring SR. Osteoimmunology and bone homeostasis: relevance to spondyloarthritis. Curr Rheumatol Rep. 2013;15:342–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Ogdie A, Schwartzman S, Eder L, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol. 2014;41:2315–22.

    Article  PubMed  CAS  Google Scholar 

  20. Borman P, Babaoğlu S, Gur G, et al. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol. 2008;27:443–7.

    Article  PubMed  Google Scholar 

  21. Busquets N, Vaquero CG, Moreno JR, et al. Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Rheumatol Clin. 2014;10:89–93.

    Google Scholar 

  22. Riesco M, Manzano F, Font P, et al. Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. Clin Rheumatol. 2013;32:1799–804.

    Article  PubMed  Google Scholar 

  23. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther. 2011;13:R16. https://doi.org/10.1186/ar3240.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Del Puente A, Esposito A, Costa L, et al. Fragility fractures in patients with psoriatic arthritis. J Rheumatol Suppl. 2015;93:36–9.

    Article  PubMed  Google Scholar 

  25. Chandran S, Aldei A, Johnson SR, et al. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: a systematic review. Semin Arthritis Rheum. 2016;46(2):174–82. https://doi.org/10.1016/j.semarthrit.2016.05.005. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  26. Kincse G, Bhattoa PH, Herédi E, et al. Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis. J Dermatol. 2015;42:679–84.

    Article  PubMed  CAS  Google Scholar 

  27. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2015;365:2205–19.

    Article  Google Scholar 

  28. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996;35:309–22.

    Article  PubMed  CAS  Google Scholar 

  29. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:885–906.

    Article  PubMed  Google Scholar 

  30. Kleyer A, Schett G. Arthritis and bone loss: a hen and egg story. Curr Opin Rheumatol. 2014;26:80–4.

    Article  PubMed  CAS  Google Scholar 

  31. Lee JH, Sung YK, Choi CB, et al. The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:98. https://doi.org/10.1186/s12891-016-0952-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum. 2000;43:522–30.

    Article  PubMed  CAS  Google Scholar 

  33. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000;27:2582–9.

    PubMed  CAS  Google Scholar 

  34. Ørstavik RE, Haugeberg G, Uhlig T, et al. Vertebral deformities in rheumatoid arthritis: a comparison with population based controls. Arch Intern Med. 2004;164:420–5.

    Article  PubMed  Google Scholar 

  35. van Staa T, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.

    Article  PubMed  Google Scholar 

  36. Pell NF, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis. 1995;54:801–6.

    Article  Google Scholar 

  37. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Adami S, Bianchi G, Brandi ML, et al. Validation and further development of the WHO 10-year fracture risk assessment tool in Italia postmenopausal women: project rationale and description. Clin Exp Rheumatol. 2010;28:561–70.

    PubMed  CAS  Google Scholar 

  39. Vis M, Guler-Yuksel M, Lems WF. Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int. 2013;24:2541–53.

    Article  PubMed  CAS  Google Scholar 

  40. Miao CG, Yang YY, He X, et al. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal. 2013;25:2069–78.

    Article  PubMed  CAS  Google Scholar 

  41. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333:142–6.

    Article  PubMed  CAS  Google Scholar 

  42. Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:3371–80.

    Article  PubMed  CAS  Google Scholar 

  43. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52:3360–70.

    Article  PubMed  CAS  Google Scholar 

  44. Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2013;18:1319–28.

    Article  CAS  Google Scholar 

  45. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82–8.

    Article  PubMed  CAS  Google Scholar 

  46. Pereira RMR, de Carvalho JF, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics. 2010;65:1197–205.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Martin JC, Munro R, Campbell MK. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol. 1997;36:43–9.

    Article  PubMed  CAS  Google Scholar 

  48. Hall GM, Spector TD, Griffin AJ, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 1993;36:1510–6.

    Article  PubMed  CAS  Google Scholar 

  49. Sambrook PN, Eisman JA, Champion GD, Yeates MG, et al. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum. 1987;30:721–8.

    Article  PubMed  CAS  Google Scholar 

  50. Kroger H, Honkanen R, Saarikoski S, et al. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis. 1994;53:18–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Haugeberg G, Uhlig T, Falch JA, et al. Reduced bone mineral density in male rheumatoid arthritis patients. Arthritis Rheum. 2000;43:2776–84.

    Article  PubMed  CAS  Google Scholar 

  52. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;344:23–7.

    Article  PubMed  CAS  Google Scholar 

  53. Fassio A, Idolazzi L, Jaber MA, et al. The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo. 2016;68:65–71.

    Article  PubMed  CAS  Google Scholar 

  54. Peng J, Gong Y, Zhang Y, et al. Bone mineral density in patients with rheumatoid arthritis and 4-year follow-up results. J Clin Rheumatol. 2016;22:71–4.

    Article  PubMed  Google Scholar 

  55. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1–12.

    Article  PubMed  Google Scholar 

  56. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329–39.

    Article  PubMed  Google Scholar 

  57. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis. 2004;63:1576–80.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Orstavik RE, Haugeberg G, Uhlig T, et al. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis. 2004;63:177–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Huusko TM, Korpela M, Karppi P, et al. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis. 2001;60:521–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Ghazi M, Kolta S, Briot K, et al. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int. 2012;23:581–7.

    Article  PubMed  CAS  Google Scholar 

  61. Orstavik RE, Haugeberg G, Mowinckel P, et al. Vertebral deformities in rheumatoid arthritis. Arch Intern Med. 2004;164:420–5.

    Article  PubMed  Google Scholar 

  62. Okano T, Inui K, Tada M, et al. High frequency of vertebral fracture and low bone quality in patients with rheumatoid arthritis—results from TOMORROW study. Mod Rheumatol. 2016;2:1–7. [Epub ahead of print].

    Google Scholar 

  63. Ochi K, Inoue E, Furuya T, Ikari K, et al. Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int. 2015;26:961–8.

    Article  PubMed  CAS  Google Scholar 

  64. Chopin F, Garnéro P, le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:353–7.

    Article  PubMed  CAS  Google Scholar 

  65. Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009;68:1898–901.

    Article  PubMed  CAS  Google Scholar 

  66. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:420–7.

    Article  PubMed  CAS  Google Scholar 

  68. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1508–12.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wijbrandts CA, Klaasen R, Dijkgraaf MGW, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68:373–6.

    Article  PubMed  CAS  Google Scholar 

  70. Krieckaert CL, Nurmohamed MT, Wolbink G, et al. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52:547–53.

    Article  CAS  Google Scholar 

  71. Roussy JP, Bessette L, Bernatsky S, et al. Biologic disease-modifying anti-rheumatic drugs and the risk of nonvertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. Osteoporos Int. 2013;24:2483–92.

    Article  PubMed  Google Scholar 

  72. Coulson KA, Reed G, Gilliam BE, et al. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15:155–60.

    Article  PubMed  Google Scholar 

  73. Kim SY, Schneeweiss S, Liu J, et al. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012;27:789–96.

    Article  PubMed  CAS  Google Scholar 

  74. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878–88.

    Article  PubMed  Google Scholar 

  75. Bultink IEM, Harvey NC, Lalmohamed A, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int. 2014;25:1275–83.

    Article  PubMed  CAS  Google Scholar 

  76. Cramarossa C, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus. 2016;26(4):365–72. pii: 0961203316664597. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  77. Edens C, Robinson AB. Systemic lupus erythematosus, bone health, and osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2015;22:422–31.

    Article  PubMed  CAS  Google Scholar 

  78. Schmajuk G, Yelin E, Chakravarty E, et al. Osteoporosis screening, prevention and treatment in systemic lupus erythematosus: application of systemic lupus erythematosus quality indicators. Arthritis Care Res (Hoboken). 2010;62:993–1001.

    Article  Google Scholar 

  79. Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Osteoporos Int. 2016;27:1413–23.

    Article  PubMed  CAS  Google Scholar 

  80. Bultink IEM, Lems WF. Systemic lupus erythematosus and fractures. RMD Open. 2016;1(Suppl 1):e000069. [Epub ahead of print].

    Article  Google Scholar 

  81. Li EK, Tam LS, Griffith JF, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36:1646–52.

    Article  PubMed  Google Scholar 

  82. Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med. 2016;3(1):e000098. [Epub ahead of print].

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. García-Carrasco M, Mendoza-Pint C, Riebeling C, et al. Influence of prevalent vertebral fractures on the quality of life patients with systemic lupus erythematosus. Isr Med Assoc J. 2011;13:333–7.

    PubMed  Google Scholar 

  84. Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus: a systematic review. PharmacoEconomics. 2013;31:49–61.

    Article  PubMed  Google Scholar 

  85. Di Munno O, Mazzantini M, Delle Sedie A, et al. Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus. 2004;13:724–30.

    Article  PubMed  Google Scholar 

  86. Sun YN, Feng XY, He L, et al. Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus. Biomed Res Int. 2015;2015:510514. [Epub ahead of print].

    PubMed  PubMed Central  Google Scholar 

  87. Bultink IEM, Vis M, van der Horst-Bruinsma IE, et al. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14:224–30.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Bonfá AC, Seguro LPC, Caparbo V, et al. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int. 2015;26:1563–71.

    Article  PubMed  CAS  Google Scholar 

  89. Fisher A, Srikusalanukul W, Davis M, et al. Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging. 2013;8:239–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Farhat GN, Newman AB, Sutton-Tyrrell K. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int. 2007;18:999–1008.

    Article  PubMed  CAS  Google Scholar 

  91. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77–95.

    Article  PubMed  Google Scholar 

  92. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708–19.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Ajeganova S, Gustafsson T, Jogestrand T, et al. Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study. Arthritis Res Ther. 2015;17:84–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Bultink IEM, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;54:2044–50.

    Article  Google Scholar 

  95. Bhattoa HP, Kiss E, Bettembuk P, et al. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int. 2001;21:97–102.

    Article  PubMed  CAS  Google Scholar 

  96. Zhu TY, Griffith JF, Au SK. Bone mineral density change in systemic lupus erythematosus: a 5-year followup study. J Rheumatol. 2014;41:1990–7.

    Article  PubMed  Google Scholar 

  97. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins lupus cohort: an update. Arthritis Care Res. 1995;8:137–45.

    Article  PubMed  CAS  Google Scholar 

  98. Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:579–85.

    Article  PubMed  Google Scholar 

  99. Almehed K, Forsblad d’Elia H, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford). 2007;46:1185–90.

    Article  CAS  Google Scholar 

  100. Mok CC. Vitamin D and systemic lupus erythematosus: an update. Expert Rev Clin Immunol. 2013;9:453–63.

    Article  PubMed  CAS  Google Scholar 

  101. Reynolds JA, Bruce IN. Vitamin D treatment for connective tissue diseases: hope beyond the hype? Rheumatology (Oxford). 2016;56(2):178–86. pii: kew212. [Epub ahead of print].

    Article  Google Scholar 

  102. Salman-Monte TC, Torrente-Segarra V, Almirall M, et al. Prevalence and predictors of vitamin D insufficiency in supplemented and non-supplemented women with systemic lupus erythematosus in the Mediterranean region. Rheumatol Int. 2016;36:975–85.

    Article  PubMed  CAS  Google Scholar 

  103. Yeap SS, Othman AZ, Zain AA, et al. Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int J Rheum Dis. 2012;15:17–24.

    Article  PubMed  CAS  Google Scholar 

  104. Guo Q, Fan P, Luo J, et al. Assessment of bone mineral density and bone metabolism in young male adults recently diagnosed with systemic lupus erythematosus in China. Lupus. 2016;26(3):289–93. pii: 0961203316664596. [Epub ahead of print].

    Article  PubMed  CAS  Google Scholar 

  105. Jacobs J, Korswagen LA, Schilder AM, et al. Six-years follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int. 2013;24:1827–33.

    Article  PubMed  CAS  Google Scholar 

  106. Cutolo M. Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann Rheum Dis. 2013;72:473–5.

    Article  PubMed  CAS  Google Scholar 

  107. Prietl B, Treiber G, Pieber TR, et al. Vitamin D and immune function. Forum Nutr. 2013;5:2502–21.

    CAS  Google Scholar 

  108. Watad A, Neumann SG, Soriano A, et al. Vitamin D and systemic lupus erythematosus: myth or reality? Isr Med Assoc J. 2016;18:177–82.

    PubMed  Google Scholar 

  109. Ritterhouse LL, Crow SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1569–74.

    Article  PubMed  CAS  Google Scholar 

  110. Durcan L, Petri M. Immunomodulators in SLE: clinical evidence and immunologic actions. J Autoimmun. 2016;74(16):30088–9. https://doi.org/10.1016/j.jaut.2016.06.010. [Epub ahead of print].

    Article  CAS  Google Scholar 

  111. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2015;14:106–12.

    Article  Google Scholar 

  112. Lakshminarayanan S, Walsh S, Mohanraj M, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102–8.

    PubMed  CAS  Google Scholar 

  113. Mok CC, Ying SK, To CH, et al. Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone. 2008;43:327–31.

    Article  PubMed  Google Scholar 

  114. Mazzantini M, Di Munno O. Glucocorticoid-induced osteoporosis: 2013 update. Reumatismo. 2014;66:144–52.

    Article  PubMed  CAS  Google Scholar 

  115. Zhu TY, Griffith JF, Qin L, et al. Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study. Osteoporos Int. 2015;26:1759–71.

    Article  PubMed  CAS  Google Scholar 

  116. Mak A, Lim JQ, Liu Y, et al. Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol Int. 2013;33:299–307.

    Article  PubMed  Google Scholar 

  117. Lee JJ, Aghdassi E, Cheung AM, et al. Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. J Rheumatol. 2012;39:1378–84.

    Article  PubMed  Google Scholar 

  118. FRAX® tool. http://www.shef.ac.uk/FRAX. Assessed 9 Sept 2011

  119. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515–26.

    Article  Google Scholar 

  120. Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2012;91:225–43.

    Article  PubMed  CAS  Google Scholar 

  121. Francis RM, Aspray TJ, Boering CE, et al. National Osteoporosis Society practical clinical guideline on vitamin D and bone health. Maturitas. 2015;80:119–21.

    Article  PubMed  CAS  Google Scholar 

  122. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.

    Article  CAS  PubMed  Google Scholar 

  123. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346–55.

    Article  PubMed  CAS  Google Scholar 

  124. Baron R, Ferrari S, Graham R, et al. Denosumab and bisphosphonates: different mechanisms of actions and effects. Bone. 2011;48:677–92.

    Article  PubMed  CAS  Google Scholar 

  125. Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pisa, Pisa, Italy

    Ombretta Di Munno

  2. “Sant’Orsola-Malpighi” Hospital, Bologna, Italy

    Nazzarena Malavolta

  3. “San Camillo” Hospital, Rome, Italy

    Giovanni Minisola

Authors
  1. Ombretta Di Munno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nazzarena Malavolta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Minisola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Minisola .

Editor information

Editors and Affiliations

  1. Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

    Andrea Lenzi

  2. Department of Movement, Human and Health Sciences, Foro Italico University of Rome, Rome, Italy

    Silvia Migliaccio

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Di Munno, O., Malavolta, N., Minisola, G. (2018). Rheumatic Diseases and Osteoporosis. In: Lenzi, A., Migliaccio, S. (eds) Multidisciplinary Approach to Osteoporosis. Springer, Cham. https://doi.org/10.1007/978-3-319-75110-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75110-8_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75108-5

  • Online ISBN: 978-3-319-75110-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation